News about Clinical Trials

Roche's Fenebrutinib Becomes First Investigational Therapy in Over a Decade to Slow Disability Progression in PPMS

Roche reported positive late-breaking Phase III ACTRIMS data showing fenebrutinib reduced disability progression in Primary Progressive Multiple Sclerosis (PPMS), demonstrating non-inferiority to OCREVUS and reinforcing its potential as a first-in-class oral BTK inhibitor.

Clinical Trials | 09/02/2026 | By News Bureau |  182

Alvotech Announces Positive Results from Pharmacokinetic Study for Entyvio

Alvotech has reported positive top-line results from a pivotal pharmacokinetic study of AVT80, its proposed biosimilar to Entyvio. The study met all primary endpoints, demonstrating comparable pharmacokinetics, safety, tolerability and immunogenicity to the reference product in healthy adult participants.

Clinical Trials | 06/02/2026 | By News Bureau |  119

Pfizer's Monthly Injectable GLP-1 Shows Sustained Weight Loss

Pfizer’s phase-II (b) VESPER-III study demonstrated that its ultra-long-acting injectable GLP-1 receptor agonist PF-08653944 delivered statistically significant and sustained weight loss with monthly dosing, supporting its advancement into an expansive phase-III obesity programme planned for 2026.

Clinical Trials | 04/02/2026 | By News Bureau |  310

Avobis Bio to Present Expanded STOMP2 Trial Data on AVB-114 at ECCO Congress

Expanded STOMP2 trial data highlight sustained safety and efficacy of AVB-114, as Avobis Bio prepares for Phase III development in Crohn’s disease.

Clinical Trials | 30/01/2026 | By News Bureau |  250

SK Bioscience Begins Study of Sarbecovirus Vaccine

SK bioscience has initiated a global phase I/II clinical trial of GBP511, a universal vaccine candidate targeting the Sarbecovirus family, leveraging its SKYCovione recombinant protein platform and nanoparticle technology as part of the company’s mid- to long-term strategy to advance next-generation vaccines for future pandemic preparedness.

Clinical Trials | 30/01/2026 | By News Bureau |  131

Boehringer Ingelheim's Apecotrep Cuts Proteinuria by 40 percent in Phase II Trial for Rare Kidney Disease FSGS

Phase II data show apecotrep, a first-in-class oral TRPC6 inhibitor, significantly reduced proteinuria in patients with primary FSGS, supporting ongoing Phase III development.

Clinical Trials | 29/01/2026 | By News Bureau |  244

QureBio Reports Promising Phase Ib/II Data for Q-1802 in Advanced Gastric and GEJ Cancer

ASCO 2026 data show strong response rates and manageable safety for the bispecific antibody Q-1802 plus XELOX, supporting progression to a Phase III trial.

Clinical Trials | 29/01/2026 | By News Bureau |  355

Eisai Submits EMA Application for Once-Monthly Maintenance Dosing of Alzheimer's Drug Lecanemab

BioArctic partner Eisai has filed a Marketing Authorisation Variation with the EMA seeking approval for a once-every-four-weeks IV maintenance dosing regimen for lecanemab in early Alzheimer’s disease.

Clinical Trials | 27/01/2026 | By News Bureau |  122

FIU Researchers Advance Functional Precision Medicine for Hard to Treat Cancers

FIU researchers are advancing functional precision medicine for hard-to-treat cancers, with new funding accelerating drug sensitivity testing to identify personalized, effective therapies beyond conventional genetic approaches.

Clinical Trials | 22/01/2026 | By News Bureau |  200

Moderna and Merck Show Durable Five-Year Benefit for Intismeran-KEYTRUDA in Melanoma

At a median five-year follow-up, intismeran autogene plus KEYTRUDA reduced recurrence or death risk by 49 percent versus KEYTRUDA alone, with further data expected and multiple late-stage trials ongoing across tumour types.

Clinical Trials | 22/01/2026 | By News Bureau |  138